Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Mallinckrodt
Medtronic
Johnson and Johnson
Harvard Business School

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DAUNORUBICIN HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Daunorubicin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002093 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed Nexstar Pharmaceuticals Phase 3 1969-12-31 To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered in combination with antiretroviral therapy. To compare the duration of responses, response rates, and times to response.
NCT00002471 Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma Completed Memorial Sloan Kettering Cancer Center Phase 2 1990-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have acute B-lymphoblastic leukemia or recurrent non-Hodgkin's lymphoma.
NCT00002499 Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia Unknown status Grupo Argentino de Tratamiento de la Leucemia Aguda Phase 2/Phase 3 1990-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II/III trial to study the effectiveness of combination chemotherapy in treating children with relapsed acute lymphocytic leukemia.
NCT00002514 Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed Medical Research Council Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Daunorubicin Hydrochloride

Condition Name

Condition Name for Daunorubicin Hydrochloride
Intervention Trials
Leukemia 88
Acute Myeloid Leukemia 68
Untreated Adult Acute Myeloid Leukemia 23
Acute Lymphoblastic Leukemia 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Daunorubicin Hydrochloride
Intervention Trials
Leukemia 271
Leukemia, Myeloid, Acute 170
Leukemia, Myeloid 157
Precursor Cell Lymphoblastic Leukemia-Lymphoma 112
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Daunorubicin Hydrochloride

Trials by Country

Trials by Country for Daunorubicin Hydrochloride
Location Trials
Australia 93
Spain 54
Germany 39
United Kingdom 32
France 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Daunorubicin Hydrochloride
Location Trials
California 84
New York 84
Illinois 77
Ohio 75
Texas 72
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Daunorubicin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Daunorubicin Hydrochloride
Clinical Trial Phase Trials
Phase 4 21
Phase 3 101
Phase 2/Phase 3 10
[disabled in preview] 94
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Daunorubicin Hydrochloride
Clinical Trial Phase Trials
Completed 121
Recruiting 77
Active, not recruiting 35
[disabled in preview] 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Daunorubicin Hydrochloride

Sponsor Name

Sponsor Name for Daunorubicin Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 109
Children's Oncology Group 32
PETHEMA Foundation 11
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Daunorubicin Hydrochloride
Sponsor Trials
Other 341
NIH 112
Industry 91
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Mallinckrodt
McKesson
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.